Neuren Pharmaceuticals Ltd (NEU.AU) saw its stock price plummet 5.20% during intraday trading on Wednesday.
The sharp decline followed the company's announcement that it is reassessing its capital management options and has decided to pause its share buyback program. Neuren Pharmaceuticals stated it will confirm the outcome of this assessment in August.